Recursion Pharmaceuticals Forecast, price target & analysts
Why the stock moved Beta
Recursion Pharmaceuticals Target price 2025 - Analyst rating & recommendation
Recursion Pharmaceuticals Classifications & Recommendation:
Recursion Pharmaceuticals Price Target
| Target Price | $6.12 |
| Price | $4.92 |
| Potential |
24.39%
register free of charge
|
| Number of Estimates | 8 |
|
8 Analysts have issued a price target Recursion Pharmaceuticals 2026 .
The average Recursion Pharmaceuticals target price is $6.12.
This is
24.39%
register free of charge
$10.50
113.41%
register free of charge
$3.03
38.41%
register free of charge
|
|
| A rating was issued by 14 analysts: 7 Analysts recommend Recursion Pharmaceuticals to buy, 7 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Recursion Pharmaceuticals stock has an average upside potential 2026 of
24.39%
register free of charge
|
Sales and Margin forecast 2025, 2026 & 2027
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 58.84 | 73.06 |
| 31.99% | 24.17% | |
| EBITDA Margin | -782.12% | -887.48% |
| 2.44% | 13.47% | |
| Net Margin | -788.00% | -1,099.71% |
| 7.08% | 39.56% |
12 Analysts have issued a sales forecast Recursion Pharmaceuticals 2025 . The average Recursion Pharmaceuticals sales estimate is
This results in the following potential growth metrics:
7 Analysts have issued an Recursion Pharmaceuticals EBITDA forecast 2025. The average Recursion Pharmaceuticals EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
12 Recursion Pharmaceuticals Analysts have issued a net profit forecast 2025. The average Recursion Pharmaceuticals net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 & 2027
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.69 | -1.64 |
| 6.96% | 2.96% | |
| P/E | negative | |
| EV/Sales | 24.50 |
12 Analysts have issued a Recursion Pharmaceuticals forecast for earnings per share. The average Recursion Pharmaceuticals EPS is
This results in the following potential growth metrics and future valuations:
Recursion Pharmaceuticals...
Current Recursion Pharmaceuticals Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Needham |
Locked
➜
Locked
|
Locked | Sep 11 2025 |
| Needham |
Locked
➜
Locked
|
Locked | Jul 08 2025 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Jun 16 2025 |
| Needham |
Locked
➜
Locked
|
Locked | May 06 2025 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Apr 10 2025 |
| Needham |
Locked
➜
Locked
|
Locked | Apr 08 2025 |
| Leerink Partners |
Locked
➜
Locked
|
Locked | Feb 28 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Needham:
Locked
➜
Locked
|
Sep 11 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
Jul 08 2025 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Jun 16 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
May 06 2025 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Apr 10 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
Apr 08 2025 |
|
Locked
Leerink Partners:
Locked
➜
Locked
|
Feb 28 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
